摘要
目的探讨TE与TEC方案在乳腺癌新辅助化疗中的近期疗效及不良反应。方法将200例乳腺癌患者随机分为TE组和TEC组,各为100例。TE组采用TE方案进行治疗,TEC组采用TEC方案治疗。记录和比较分析2组的近期疗效(CR、c CR、p CR、PR、PD、SD)及不良反应(血红蛋白减少、血小板减少、粒细胞减少、胃肠道反应、脱发)。结果TE组和TEC组患者的CR、c CR、p CR、PR、SD、PD的比率分别为81%、67%、14%、12%、6%、1%与79%、69%、10%、13%、7%、1%,2组相比较,差异均无统计学意义(P>0.05)。TE组和TEC组胃肠道反应的发生率分别为51%和78%,差异有统计学意义(χ2=15.9188,P=0.0001);TE组和TEC组粒细胞减少的发生率分别为20%和33%,差异有统计学意义(χ2=4.3383,P=0.0373);TE组和TEC组的血红蛋白减少、血小板减少、脱发的发生率比较无统计学差异。结论TE与TEC方案在乳腺癌新辅助化疗中的近期疗效大致相当,但TE方案的不良反应发生率较低,值得临床推广。
Objective To investigate the short-term efficacy and toxicity of TE and TEC in neoadjuvant chemotherapy for breast cancer. Methods 200 patients with breast cancer were randomly divided into TE group and TEC group,each with 100 patients,TE group was treated by TE program,while TEC group was treated by TEC program. Short-term efficacy( CR,c CR,p CR,PR,PD,SD) and toxicities( hemoglobin decrease,thrombocytopenia,neutropenia,gastrointestinal reactions,alopecia) of the 2 group were recorded and compared. Results The rates of CR,c CR,p CR,PR,SD,PD of TE group and TEC group were 81%,67%,14%,12%,6%,1% and 79%,69%,10%,13%,7%,1%,there was no significant difference between them( P > 0. 05); the occurrence rates of gastrointestinal reactions of TE group and TEC group were 51% and 78%,there was a significant difference between them( χ2= 15. 9188,P = 0. 0001); neutropenia rates of TE group and the TEC group were 20% and 33%,there was a significant differences( χ2= 4. 3383,P = 0. 0373); Hemoglobin decrease,thrombocytopenia,and alopecia of TE group and TEC group had no significant difference. Conclusion The short-term efficacy of TE and TEC in neoadjuvant chemotherapy for breast cancer are similar,but TE has less toxicity. It is worthy of promotion in clinic.
出处
《实用癌症杂志》
2015年第3期445-447,共3页
The Practical Journal of Cancer
